RECURSION PHARMACEUTICALS, INC.(RXRX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

RECURSION PHARMACEUTICALS, INC. (RXRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RXRX at 23.3/100 on a 32-signal composite quality model, placing it at rank #2,729 of 2,960 stocks — the bottom half of the AI-ranked universe. RXRX scores in the top quartile across institutional flow (88.8). Areas of concern include free cash flow (2.3) and profitability (2.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), RECURSION PHARMACEUTICALS, INC. reports quarterly revenue of $7.7M, net income of $-131.0M, free cash flow of $-106.0M. Top institutional holders of RXRX by reported 13-F value include BlackRock, ARK Investment Management, STATE STREET, based on the most recent SEC filings. RXRX trades on the Nasdaq exchange and files with the SEC under CIK 1601830. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RXRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RECURSION PHARMACEUTICALS, INC. directly from SEC EDGAR.